A Type D meeting was held with the FDA in March 2025 to discuss the potential regulatory path for OPGx-LCA5, including the ...

The Company reported a net loss of approximately $6.4 million, or $0.13 per share, for the three months ended March 31, 2025, ...

ADC Therapeutics SA (NYSE: ADCT) Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings ...

Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ETCompany ParticipantsRodrigo Araujo - Chief Financial & ...

Q1 2025 Earnings Call Transcript May 9, 2025Hawaiian Electric Industries, Inc. reports earnings inline with expectations.

Q1 2025 Results Conference Call May 15, 2025 3:30 AM ETCompany ParticipantsJinggay Nograles - Head of Investor RelationsDanny Yu ...

STEP Energy Services Ltd. (the "Company" or "STEP") (TSX: STEP) is pleased to announce its financial and operating results ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Air traffic controllers in Denver had to scramble to use backup frequencies after their main communications lines went down ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Annou ...